NASDAQ:VIR Vir Biotechnology (VIR) Stock Price, News & Analysis $8.37 -0.50 (-5.61%) Closing price 11/20/2026 03:58 PM EasternExtended Trading$8.48 +0.10 (+1.23%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Vir Biotechnology Stock (NASDAQ:VIR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vir Biotechnology alerts:Sign Up Key Stats Today's Range$8.34▼$8.9250-Day Range$8.37▼$13.6552-Week Range$5.45▼$14.38Volume3.09 million shsAverage Volume2.94 million shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$22.57Consensus RatingModerate Buy Company Overview Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases and cancer. Its research draws on immunology and includes approaches such as monoclonal antibodies, small-interfering RNA therapies and T-cell-based treatments. The company’s pipeline has included programs targeting chronic hepatitis B and influenza, as well as investigational cancer therapies. Vir has also pursued research and development collaborations to advance its programs. Historically, Vir partnered with GlaxoSmithKline to develop sotrovimab, an antibody treatment for COVID-19. Vir is headquartered in San Francisco, California.AI Generated. May Contain Errors. Read More Vir Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreVIR MarketRank™: 2.1018222284 of 5 starsVir Biotechnology scored higher than 42% of companies evaluated by MarketBeat, and ranked 535th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingVir Biotechnology has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialVir Biotechnology has a consensus price target of $22.57, representing about 169.6% upside from its current price of $8.37.Amount of Analyst CoverageVir Biotechnology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vir Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Vir Biotechnology are expected to decrease in the coming year, from ($1.28) to ($2.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vir Biotechnology is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vir Biotechnology is -6.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVir Biotechnology has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.15% of the float of Vir Biotechnology has been sold short.Short Interest Ratio / Days to CoverVir Biotechnology has a short interest ratio ("days to cover") of 11.86, which indicates bearish sentiment.Change versus previous monthShort interest in Vir Biotechnology has recently increased by 3.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVir Biotechnology does not currently pay a dividend.Dividend GrowthVir Biotechnology does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.45 News SentimentVir Biotechnology has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vir Biotechnology this week, compared to 6 articles on an average week.Search Interest5 people have searched for VIR on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Vir Biotechnology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Vir Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,934.00 in company stock.Percentage Held by Insiders2.90% of the stock of Vir Biotechnology is held by insiders.Percentage Held by Institutions65.32% of the stock of Vir Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vir Biotechnology's insider trading history. Receive VIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VIR Stock News HeadlinesVir Biotechnology (NASDAQ:VIR) Stock Price Crosses Below 200-Day Moving Average - Time to Sell?November 17, 2026 | americanbankingnews.comWhy Vir Biotechnology shares are trading lower todayNovember 13, 2026 | msn.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing. | Decentralized Masters (Ad)Vir Biotechnology Shares Fall After $150 Million Stock Offering Is PricedNovember 13, 2026 | marketwatch.comWhy is Vir Biotechnology stock falling Friday?November 13, 2026 | msn.comVir Biotechnology Shares Drop as Biotech Firm Moves Ahead With Stock SaleNovember 13, 2026 | finance.yahoo.comVir Biotechnology Shares Fall 18% On Pricing Of $150 Mln Shares OfferingNovember 13, 2026 | rttnews.comVir Biotechnology (NASDAQ:VIR) EVP Sells $15,216.19 in StockNovember 5, 2026 | insidertrades.comSee More Headlines VIR Stock Analysis - Frequently Asked Questions How have VIR shares performed this year? Vir Biotechnology's stock was trading at $6.03 on January 1st, 2026. Since then, VIR shares have increased by 38.8% and is now trading at $8.3720. How were Vir Biotechnology's earnings last quarter? Vir Biotechnology, Inc. (NASDAQ:VIR) issued its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.18. The firm's revenue was down 178.3% on a year-over-year basis. Read the conference call transcript. When did Vir Biotechnology IPO? Vir Biotechnology (VIR) raised $150 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,142,858 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays served as the underwriters for the IPO. Who are Vir Biotechnology's major shareholders? Top institutional shareholders of Vir Biotechnology include State Street Corp (4.57%), Pictet Asset Management Holding SA (1.13%), Goldman Sachs Group Inc. (0.49%) and Candriam S.C.A. (0.36%). Insiders that own company stock include Endurance (Cayman) Ltd Svf, Vicki L Sato, Backer Marianne De, George A Scangos, Phillip Pang, Jason O'byrne, Mark Eisner, Ann M Hanly, Verneuil Vanina De, Brent Sabatini, Janet Napolitano and Saira Ramasastry. View institutional ownership trends. How do I buy shares of Vir Biotechnology? Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vir Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vir Biotechnology investors own include Tesla (TSLA), Advanced Micro Devices (AMD), NVIDIA (NVDA), Moderna (MRNA), Novavax (NVAX), Inovio Pharmaceuticals (INO) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings11/04/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 As of 5 days ago, VIR's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VIR CIK1706431 Webwww.vir.bio Phone415-906-4324FaxN/AEmployees367Year Founded2016Price Target and Rating Average Price Target for Vir Biotechnology$22.57 High Price Target$30.00 Low Price Target$18.00 Potential Upside/Downside+169.6%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$437.99 million Net MarginsN/A Pretax Margin-61.00% Return on Equity-21.38% Return on Assets-16.97% Debt Debt-to-Equity RatioN/A Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual Sales$68.56 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$5.23 per share Price / Book1.60Miscellaneous Outstanding Shares171,270,000Free Float166,304,000Market Cap$1.43 billion OptionableOptionable Beta1.70 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:VIR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredAre Tesla and SpaceX Going Bankrupt?Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. E...Brownstone Research | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.